Novo Nordisk insulin products
Executive Summary
Intermediate-acting insulin product Novolin 85/15 Penfill received an April 14 "approvable" letter. The product was mischaracterized in the May 1 "The Pink Sheet" (p. 15). Novo Nordisk is developing a long-acting insulin product, insulin detemir, which is currently in Phase III. The company also has a short-acting insulin analog, NovoLog, under review at FDA